In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Abstract Background A new generation of radiolabeled minigastrin analogs delivers low radiation doses to kidneys and are considered relatively stable due to less enzymatic degradation. Nevertheless, relatively low tumor radiation doses in patients indicate limited stability in humans. We aimed at ev...

Full description

Bibliographic Details
Main Authors: Christof Rottenburger, Michael Hentschel, Markus Fürstner, Lisa McDougall, Danijela Kottoros, Felix Kaul, Rosalba Mansi, Melpomeni Fani, A. Hans Vija, Roger Schibli, Susanne Geistlich, Martin Behe, Emanuel R. Christ, Damian Wild
Format: Article
Language:English
Published: SpringerOpen 2024-04-01
Series:EJNMMI Research
Subjects:
Neutral endopeptidase 1
Endopeptidase inhibition
Cholecystokinin-2 receptor targeting
Peptide receptor radionuclide therapy
[177Lu]Lu-PP-FF11N
Online Access:https://doi.org/10.1186/s13550-024-01101-w

Internet

https://doi.org/10.1186/s13550-024-01101-w

Similar Items